Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat

J. D. Geiger, J. L. Lewis, C. J. MacIntyre, J. I. Nagy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The distribution of the potent inhibitor of adenosine deaminase (ADA), 2′-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t 1 2 phases of about 1-5 hr and 50 hr. The activity of ADA in gut exhibited dose-related inhibition at 1.9, 3.7 and 18.6 μmol/kg (i.p.) and returned to normal by 16 days. In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 μmol/kg. The t 1 2 of the recovery of the activity of ADA in both brain and gut was found to be dose-dependent. The failure of the activity of ADA in brain to recover after treatment with 18.6 μmol/kg suggests either long-term down-regulation of the expression of ADA or irreversible damage to ADA-containing neurons.

Original languageEnglish (US)
Pages (from-to)1383-1387
Number of pages5
JournalNeuropharmacology
Volume26
Issue number9
DOIs
StatePublished - Sep 1987

Fingerprint

Adenosine Deaminase Inhibitors
Pentostatin
Adenosine Deaminase
Pharmacokinetics
Brain
rat Ada protein
Intraperitoneal Injections
Down-Regulation
Neurons
Injections

Keywords

  • 2'-deoxycoformycin
  • adenosine deaminase
  • pharmacokinetics
  • rat brain

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. / Geiger, J. D.; Lewis, J. L.; MacIntyre, C. J.; Nagy, J. I.

In: Neuropharmacology, Vol. 26, No. 9, 09.1987, p. 1383-1387.

Research output: Contribution to journalArticle

Geiger, J. D. ; Lewis, J. L. ; MacIntyre, C. J. ; Nagy, J. I. / Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat. In: Neuropharmacology. 1987 ; Vol. 26, No. 9. pp. 1383-1387.
@article{be2797b0870648ec94f2126ef8226663,
title = "Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat",
abstract = "The distribution of the potent inhibitor of adenosine deaminase (ADA), 2′-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t 1 2 phases of about 1-5 hr and 50 hr. The activity of ADA in gut exhibited dose-related inhibition at 1.9, 3.7 and 18.6 μmol/kg (i.p.) and returned to normal by 16 days. In brain, ADA was inhibited by about 95{\%} at all three of these doses of DCF 2hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66{\%} of control levels at 50 days with 18.6 μmol/kg. The t 1 2 of the recovery of the activity of ADA in both brain and gut was found to be dose-dependent. The failure of the activity of ADA in brain to recover after treatment with 18.6 μmol/kg suggests either long-term down-regulation of the expression of ADA or irreversible damage to ADA-containing neurons.",
keywords = "2'-deoxycoformycin, adenosine deaminase, pharmacokinetics, rat brain",
author = "Geiger, {J. D.} and Lewis, {J. L.} and MacIntyre, {C. J.} and Nagy, {J. I.}",
year = "1987",
month = "9",
doi = "10.1016/0028-3908(87)90103-1",
language = "English (US)",
volume = "26",
pages = "1383--1387",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of 2′-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat

AU - Geiger, J. D.

AU - Lewis, J. L.

AU - MacIntyre, C. J.

AU - Nagy, J. I.

PY - 1987/9

Y1 - 1987/9

N2 - The distribution of the potent inhibitor of adenosine deaminase (ADA), 2′-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t 1 2 phases of about 1-5 hr and 50 hr. The activity of ADA in gut exhibited dose-related inhibition at 1.9, 3.7 and 18.6 μmol/kg (i.p.) and returned to normal by 16 days. In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 μmol/kg. The t 1 2 of the recovery of the activity of ADA in both brain and gut was found to be dose-dependent. The failure of the activity of ADA in brain to recover after treatment with 18.6 μmol/kg suggests either long-term down-regulation of the expression of ADA or irreversible damage to ADA-containing neurons.

AB - The distribution of the potent inhibitor of adenosine deaminase (ADA), 2′-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined. The accumulation of [3H]DCF in brain was maximal 2 hr after intraperitoneal injection and elimination was best described by a two compartment model having t 1 2 phases of about 1-5 hr and 50 hr. The activity of ADA in gut exhibited dose-related inhibition at 1.9, 3.7 and 18.6 μmol/kg (i.p.) and returned to normal by 16 days. In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 μmol/kg. The t 1 2 of the recovery of the activity of ADA in both brain and gut was found to be dose-dependent. The failure of the activity of ADA in brain to recover after treatment with 18.6 μmol/kg suggests either long-term down-regulation of the expression of ADA or irreversible damage to ADA-containing neurons.

KW - 2'-deoxycoformycin

KW - adenosine deaminase

KW - pharmacokinetics

KW - rat brain

UR - http://www.scopus.com/inward/record.url?scp=0023253274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023253274&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(87)90103-1

DO - 10.1016/0028-3908(87)90103-1

M3 - Article

C2 - 3499581

AN - SCOPUS:0023253274

VL - 26

SP - 1383

EP - 1387

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 9

ER -